Literature DB >> 23747780

Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.

Dimitrios Alexopoulos, Vassilios Gkizas, Sotirios Patsilinakos, Ioanna Xanthopoulou, Christos Angelidis, Prodromos Anthopoulos, George Makris, Angelos Perperis, Stavros Karanikas, Nikolaos Koutsogiannis, Periklis Davlouros, Spyridon Deftereos, John Chiladakis, George Hahalis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23747780     DOI： 10.1016/j.jacc.2013.05.021

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  11 in total

1.  Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.

Authors:  Dimitrios Alexopoulos; Nikolaos Barampoutis; Vasileios Gkizas; Chrysoula Vogiatzi; Grigorios Tsigkas; Nikolaos Koutsogiannis; Periklis Davlouros; George Hahalis; Sven Nylander; Guido Parodi; Ioanna Xanthopoulou
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

2.  [Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].

Authors:  T Bauer; C Hamm
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

3.  Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.

Authors:  Dimitrios Alexopoulos; Angelos Perperis; Ioanna Koniari; Haralambos Karvounis; Sotirios Patsilinakos; Antonios Ziakas; Nikolaos Barampoutis; Theofilos Panagiotidis; Karolina Akinosoglou; George Hahalis; Ioanna Xanthopoulou
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

4.  Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.

Authors:  Andrew Yang; Quin Pon; Andrea Lavoie; Jennifer J Crawford; Sebastian Harenberg; Rodney H Zimmermann; Jeff Booker; Sheila Kelly; Shahar Lavi; Warren J Cantor; Shamir R Mehta; Akshay Bagai; Shaun G Goodman; Asim N Cheema; Payam Dehghani
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

Review 5.  Antithrombotic therapy for patients with STEMI undergoing primary PCI.

Authors:  Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2017-02-23       Impact factor: 32.419

6.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

7.  Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.

Authors:  Jolanta M Siller-Matula; Simon Specht; Jacek Kubica; Dimitrios Alexopoulos; Raffaele De Caterina; Eva-Luise Hobl; Bernd Jilma; Günter Christ; Irene M Lang
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

Review 8.  Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update.

Authors:  Renli Teng
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 9.  Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.

Authors:  T Burt; R J Noveck; D B MacLeod; A T Layton; M Rowland; G Lappin
Journal:  Clin Transl Sci       Date:  2017-04-18       Impact factor: 4.689

10.  Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Hui-Liang Liu; Yu-Jie Wei; Zhi-Geng Jin; Jiao Zhang; Peng Ding; Sheng-Li Yang; Jian-Ping Luo; Dong-Xing Ma; Ying Liu; Wei Han
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.